<DOC>
	<DOCNO>NCT02943642</DOCNO>
	<brief_summary>This study evaluate effectiveness — judge complete response — single four-day treatment fusion protein A-dmDT390-bisFv ( UCHT1 ) compare oral Zolinza ( Vorinostat ) , randomize 2-arm trial maximum 12 month treatment . Patient eligibility stage IB/IIB mycosis fungoides mSWAT &lt; 50 never lymphoid disease prior bone marrow / HSCT transplant .</brief_summary>
	<brief_title>Safety Effectiveness A-dmDT390-bisFv ( UCHT1 ) Fusion Protein Subjects With Mycosis Fungoides</brief_title>
	<detailed_description>Primary Objective : This study objective document incidence complete response compare oral vorinostat , randomize 2-arm trial maximum 12 month treatment subject stage IB/IIB mycosis fungoides mSWAT &lt; 50 never lymphoid disease prior bone marrow / HSCT transplant . Secondary Objective : To explore toxicity profile A-dmDT390-bisFv ( UCHT1 ) fusion protein subject mycosis fungoides select free preexist cardiac disease never treat Campath . Number Subjects : Lead-in Dosing : 12 / Randomized : 162 Patients receive full supportive care course study . Participation study require IV infusion research agent 2 time day four day ( protocol FDA outpatient approve ) , well frequent outpatient blood draw first 30 day . Patients partial complete remission 1 month follow visit another follow-up visit day 60 , every three month 1 year , follow annual visit assess duration response .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Subjects must sign current IRB approve informed consent prior registration ( see Informed Consent ) . Mycosis fungoides , confirm biopsy flow cytometry , without large cell transformation . Relapse progression 2 systemic therapy . Note : Total electron beam therapy count systemic therapy . Disease stage follow : Stage IB lymph node involvement include lymphadenopathy mSWAT &lt; 50 ; Stage IIB lymph node involvement include lymphadenopathy mSWAT &lt; 50 . Age 18 year . Subjects must performance status &lt; 2 Eastern Cooperative Oncology Group scale ( see Appendix A ) . Subjects must normal lung function evaluate pulse oximetry O2 saturation value 95100 % . Subjects must fully recover toxicity prior chemotherapy radiation therapy . Subjects must : bilirubin &lt; 1.5 mg/dL , transaminases &lt; 2.5 X ULN , albumin &gt; 3 gm/dL , creatinine &lt; 2.0 mg/dL . Subjects albumin &lt; 3 gm/dL boost albumin infusion must observe maintain albumin &gt; 3gm dL 14 day without additional infusion . Subjects must normal echocardiogram ( EF &gt; 50 % normal ) without evidence cardiac chamber hypertrophy , dilatation hypokinesis . Females male must willing use approve form birth control study 2 week completion . Subjects must pretreatment antiDT titer 20 μg/ml less . Subjects titer 21 35 μg/ml additional antiDT neutralization test use subject 's serum AdmDT390bisFv ( UCHT1 ) . If neutralization find titer consider acceptable . Failure meet criterion . Inability give inform consent psychiatric problem , complicate medical problem . Allergic diphtheria toxin component study drug AdmDT390bisFv ( UCHT1 ) . Serious concurrent medical problem , uncontrolled infection , disseminate intravascular coagulopathy ( DIC ) , hepatic cirrhosis , chronic kidney disease . CNS leukemia . Preexisting cardiovascular disease . The exception well control essential hypertension sit blood pressure ( B.P . ) &lt; 160 systolic &lt; 90 diastolic without evidence structural heart disease one episode myocardial infarction &gt; 8 month ago . Subjects receive betablocker hypertension convert another antihypertensive drug class 23 week receive study drug prevent drugdrug interaction reactive tachycardia . Angiotensin inhibitor , angiotensin receptor blocker calcium channel blocker acceptable . A past history follow condition consider exclusion study participation : Congestive heart failure , Atrial fibrillation , Pulmonary hypertension , Anticoagulant drug therapy , Thromboembolic event , Cardiomyopathy myocardial infarction within past 8 month . The PI Clinical Coordinator ask verify referred subject exclusionary history list 3.2 copy verification must send Sponsor Sponsor approve enrollment . Referring physician need sign . Pregnant nursing woman exclude study . History cirrhosis liver base ChildPugh score Class B C eligible participate . Prior treatment alemtuzumab ( Campath ) similar agent procedure depress blood T cell count 50 % low limit normal . Prior history bone marrow transplant HSCT exclusion . Prior treatment vorinostat ( Prior treatment vorinostat leadin dose arm acceptable ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>MF</keyword>
	<keyword>CTCL</keyword>
	<keyword>Cutaneous T Cell Lymphoma</keyword>
</DOC>